J Rheum Dis.  2024 Oct;31(4):193-199. 10.4078/jrd.2024.0077.

Application of disease activity index in rheumatoid arthritis management in Korea

• Choi SR
• Cho SK
• Sung YK

• KMID: 2559888
• DOI: http://doi.org/10.4078/jrd.2024.0077

Abstract

Effective management of rheumatoid arthritis (RA) necessitates the accurate measurement of disease activity using a treat-totarget strategy established as a cornerstone approach. Disease activity assessment tools such as the Disease Activity Score in 28 joints (DAS28), Simplified Disease Activity Index, Clinical Disease Activity Index, and Routine Assessment of Patient Index Data 3 have been internationally validated and recognised. In Korea, the government initiated a quality assessment program mandating routine measurement of DAS28 to ensure high-quality RA management. However, whether the DAS28 is the most suitable disease activity measurement tool in the Korean clinical environment is a topic worth considering. In this review, we comprehensively examined disease activity measurement tools and their performance in the Korean context. We also propose a new strategy for measuring RA disease activity, tailored to the different situations encountered by physicians in routine clinical practice. This review may contribute to the improvement of the quality of care for patients with RA in Korea.

Keyword

Rheumatoid arthritis; Severity of illness index; Outcome assessment; Korea

Reference

1. Di Matteo A, Bathon JM, Emery P. 2023; Rheumatoid arthritis. Lancet. 402:2019–33. DOI: 10.1016/S0140-6736(23)01525-8. PMID: 27156434.

2. Finckh A, Gilbert B, Hodkinson B, Bae SC, Thomas R, Deane KD, et al. 2022; Global epidemiology of rheumatoid arthritis. Nat Rev Rheumatol. 18:591–602. DOI: 10.1038/s41584-022-00827-y. PMID: 36068354.

3. Kim H, Sung YK. 2021; Epidemiology of rheumatoid arthritis in Korea. J Rheum Dis. 28:60–7. DOI: 10.4078/jrd.2021.28.2.60. PMID: 37476013. PMCID: PMC10324889.

4. Sung YK, Cho SK, Choi CB, Bae SC. 2013; Prevalence and incidence of rheumatoid arthritis in South Korea. Rheumatol Int. 33:1525–32. DOI: 10.1007/s00296-012-2590-2. PMID: 23255140.

5. Won S, Cho SK, Kim D, Han M, Lee J, Jang EJ, et al. 2018; Update on the prevalence and incidence of rheumatoid arthritis in Korea and an analysis of medical care and drug utilization. Rheumatol Int. 38:649–56. DOI: 10.1007/s00296-017-3925-9. PMID: 29302803.

6. Lee TJ, Park BH, Son HK, Song R, Shin KC, Lee EB, et al. 2012; Cost of illness and quality of life of patients with rheumatoid arthritis in South Korea. Value Health. 15(1 Suppl):S43–9. DOI: 10.1016/j.jval.2011.11.020. PMID: 22265066.

7. Kim H, Cho SK, Kim JW, Jung SY, Jang EJ, Bae SC, et al. 2020; An increased disease burden of autoimmune inflammatory rheumatic diseases in Korea. Semin Arthritis Rheum. 50:526–33. DOI: 10.1016/j.semarthrit.2019.11.007. PMID: 31852583.

8. Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, et al. 2016; Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 75:3–15. DOI: 10.1136/annrheumdis-2015-207524. PMID: 25969430. PMCID: PMC4717393.

9. Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, et al. T2T Expert Committee. 2010; Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 69:631–7. DOI: 10.1136/ard.2009.123919. PMID: 20215140. PMCID: PMC3015099.

10. Stoffer MA, Schoels MM, Smolen JS, Aletaha D, Breedveld FC, Burmester G, et al. 2016; Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update. Ann Rheum Dis. 75:16–22. DOI: 10.1136/annrheumdis-2015-207526. PMID: 25990290. PMCID: PMC4717391.

11. Smolen JS, Landewé R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, et al. 2010; EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 69:964–75. DOI: 10.1136/ard.2009.126532. PMID: 36357155.

12. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012; 2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 64:625–39. DOI: 10.1002/acr.21641. PMID: 22473917. PMCID: PMC4081542.

13. Fraenkel L, Bathon JM, England BR, St Clair EW, Arayssi T, Carandang K, et al. 2021; 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 73:924–39. DOI: 10.1002/acr.24596. PMID: 34101387. PMCID: PMC9273041.

14. Smolen JS, Landewé RBM, Bergstra SA, Kerschbaumer A, Sepriano A, Aletaha D, et al. 2023; EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 82:3–18. DOI: 10.1136/ard-2022-223356. PMID: 36357155.

15. van Vollenhoven R. 2019; Treat-to-target in rheumatoid arthritis - are we there yet? Nat Rev Rheumatol. 15:180–6. DOI: 10.1038/s41584-019-0170-5. PMID: 30700865.

16. Lansbury J. 1956; Quantitation of the activity of rheumatoid arthritis. 5. A method for summation of the systemic indices of rheumatoid activity. Am J Med Sci. 232:300–10. DOI: 10.1097/00000441-195609000-00009. PMID: 13362243.

17. Anderson J, Caplan L, Yazdany J, Robbins ML, Neogi T, Michaud K, et al. 2012; Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care Res (Hoboken). 64:640–7. DOI: 10.1002/acr.21649. PMID: 22473918. PMCID: PMC4028066.

18. England BR, Tiong BK, Bergman MJ, Curtis JR, Kazi S, Mikuls TR, et al. 2019; 2019 Update of the American College of Rheumatology recommended rheumatoid arthritis disease activity measures. Arthritis Care Res (Hoboken). 71:1540–55. DOI: 10.1002/acr.24042. PMID: 31709779. PMCID: PMC6884664.

19. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. 1995; Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 38:44–8. DOI: 10.1002/art.1780380107. PMID: 7818570.

20. Prevoo ML, van Gestel AM, van T Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. 1996; Remission in a prospective study of patients with rheumatoid arthritis. American Rheumatism Association preliminary remission criteria in relation to the disease activity score. Br J Rheumatol. 35:1101–5. DOI: 10.1093/rheumatology/35.11.1101. PMID: 8948296.

21. van Gestel AM, Haagsma CJ, van Riel PL. 1998; Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum. 41:1845–50. DOI: 10.1002/1529-0131(199810)41:10<1845::AID-ART17>3.0.CO;2-K. PMID: 9778226.

22. Smolen JS, Han C, Bala M, Maini RN, Kalden JR, van der Heijde D, et al. ATTRACT Study Group. 2005; Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum. 52:1020–30. DOI: 10.1002/art.20982. PMID: 15818697.

23. Vander Cruyssen B, Van Looy S, Wyns B, Westhovens R, Durez P, Van den Bosch F, et al. 2005; DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatment. Arthritis Res Ther. 7:R1063–71. DOI: 10.1186/ar1787. PMID: 16207323. PMCID: PMC1257436.

24. Weinblatt ME, Keystone EC, Furst DE, Kavanaugh AF, Chartash EK, Segurado OG. 2006; Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study. Ann Rheum Dis. 65:753–9. DOI: 10.1136/ard.2005.044404. PMID: 16308341. PMCID: PMC1798163.

25. Bae SC, Cho SK, Won S, Lee HS, Lee SH, Kang YM, et al. 2018; Factors associated with quality of life and functional disability among rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs for at least 6 months. Int J Rheum Dis. 21:1001–9. DOI: 10.1111/1756-185X.12915. PMID: 29878615.

26. Song JJ, Song YW, Bae SC, Cha HS, Choe JY, Choi SJ, et al. 2018; Treat-to-target strategy for Asian patients with early rheumatoid arthritis: result of a multicenter trial in Korea. J Korean Med Sci. 33:e346. DOI: 10.3346/jkms.2018.33.e346. PMID: 30584418. PMCID: PMC6300659.

27. Park SY, Lee H, Cho SK, Choi CB, Sung YK, Bae SC. 2012; Evaluation of disease activity indices in Korean patients with rheumatoid arthritis. Rheumatol Int. 32:545–9. DOI: 10.1007/s00296-011-1798-x. PMID: 21305296.

28. Son KM, Kim SY, Lee SH, Yang CM, Seo YI, Kim HA. 2016; Comparison of the disease activity score using the erythrocyte sedimentation rate and C-reactive protein levels in Koreans with rheumatoid arthritis. Int J Rheum Dis. 19:1278–83. DOI: 10.1111/1756-185X.12698. PMID: 26200604.

29. Choi IA. 2017; Comparison of the disease activity score-28 based on the erythrocyte sedimentation rate and C-reactive protein in rheumatoid arthritis. J Rheum Dis. 24:287–92. DOI: 10.4078/jrd.2017.24.5.287.

30. Aletaha D, Smolen J. 2005; The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol. 23(5 Suppl 39):S100–8. PMID: 16273793.

31. Slama IB, Allali F, Lakhdar T, El Kabbaj S, Medrare L, Ngeuleu A, et al. 2015; Reliability and validity of CDAI and SDAI indices in comparison to DAS-28 index in Moroccan patients with rheumatoid arthritis. BMC Musculoskelet Disord. 16:268. DOI: 10.1186/s12891-015-0718-8. PMID: 26420567. PMCID: PMC4588315.

32. Dhaon P, Das SK, Srivastava R, Dhakad U. 2018; Performances of Clinical Disease Activity Index (CDAI) and Simplified Disease Activity Index (SDAI) appear to be better than the gold standard Disease Assessment Score (DAS-28-CRP) to assess rheumatoid arthritis patients. Int J Rheum Dis. 21:1933–9. DOI: 10.1111/1756-185X.13110. PMID: 28608433.

33. Koh JH, Lee Y, Kim HA, Kim J, Shin K. 2022; Comparison of remission criteria in patients with rheumatoid arthritis treated with biologic or targeted synthetic disease-modifying anti-rheumatic drugs: results from a nationwide registry. Ther Adv Musculoskelet Dis. 14:1759720X221096363. DOI: 10.1177/1759720X221096363. PMID: 35586514. PMCID: PMC9109493.

34. Pincus T, Swearingen CJ, Bergman MJ, Colglazier CL, Kaell AT, Kunath AM, et al. 2010; RAPID3 (Routine Assessment of Patient Index Data) on an MDHAQ (Multidimensional Health Assessment Questionnaire): agreement with DAS28 (Disease Activity Score) and CDAI (Clinical Disease Activity Index) activity categories, scored in five versus more than ninety seconds. Arthritis Care Res (Hoboken). 62:181–9. DOI: 10.1002/acr.20066. PMID: 20191516.

35. Bossert M, Prati C, Vidal C, Bongain S, Toussirot E, Wendling D. 2012; Evaluation of self-report questionnaires for assessing rheumatoid arthritis activity: a cross-sectional study of RAPID3 and RADAI5 and flare detection in 200 patients. Joint Bone Spine. 79:57–62. DOI: 10.1016/j.jbspin.2011.03.014. PMID: 21550283.

36. Singh H, Gupta V, Ray S, Kumar H, Talapatra P, Kaur M, et al. 2012; Evaluation of disease activity in rheumatoid arthritis by Routine Assessment of Patient Index Data 3 (RAPID3) and its correlation to Disease Activity Score 28 (DAS28) and Clinical Disease Activity Index (CDAI): an Indian experience. Clin Rheumatol. 31:1663–9. DOI: 10.1007/s10067-012-2070-9. PMID: 22983768.

37. Kim SK, Park SH, Bae J, Son JT, Choe JY. 2014; Performance of Routine Assessment of Patient Index Data 3 (RAPID3) for assessment of rheumatoid arthritis in clinical practice: differential agreement of RAPID3 according to disease activity categories. Rheumatol Int. 34:1311–8. DOI: 10.1007/s00296-014-3042-y. PMID: 24832679.

38. Kim Y, Kim GT, Suh YS, Kim HO, Lee HN, Lee SG. 2020; The impact of the amendment of the Korean National Health Insurance reimbursement criteria for anti-tumor necrosis factor-α agents on treatment pattern, clinical response and persistence in patients with rheumatoid arthritis. J Rheum Dis. 27:159–67. DOI: 10.4078/jrd.2020.27.3.159.

39. Matsui T, Kuga Y, Kaneko A, Nishino J, Eto Y, Chiba N, et al. 2007; Disease Activity Score 28 (DAS28) using C-reactive protein underestimates disease activity and overestimates EULAR response criteria compared with DAS28 using erythrocyte sedimentation rate in a large observational cohort of rheumatoid arthritis patients in Japan. Ann Rheum Dis. 66:1221–6. DOI: 10.1136/ard.2006.063834. PMID: 17369281. PMCID: PMC1955164.

40. Fleischmann R, van der Heijde D, Koenig AS, Pedersen R, Szumski A, Marshall L, et al. 2015; How much does Disease Activity Score in 28 joints ESR and CRP calculations underestimate disease activity compared with the Simplified Disease Activity Index? Ann Rheum Dis. 74:1132–7. DOI: 10.1136/annrheumdis-2013-204920. PMID: 25143522.

41. Fleischmann RM, van der Heijde D, Gardiner PV, Szumski A, Marshall L, Bananis E. 2017; DAS28-CRP and DAS28-ESR cut-offs for high disease activity in rheumatoid arthritis are not interchangeable. RMD Open. 3:e000382. DOI: 10.1136/rmdopen-2016-000382. PMID: 28255449. PMCID: PMC5294021.

42. Castrejón I, Ortiz AM, García-Vicuña R, Lopez-Bote JP, Humbría A, Carmona L, et al. 2008; Are the C-reactive protein values and erythrocyte sedimentation rate equivalent when estimating the 28-joint disease activity score in rheumatoid arthritis? Clin Exp Rheumatol. 26:769–75. PMID: 19032807.

43. Inoue E, Yamanaka H, Hara M, Tomatsu T, Kamatani N. 2007; Comparison of Disease Activity Score (DAS)28- erythrocyte sedimentation rate and DAS28- C-reactive protein threshold values. Ann Rheum Dis. 66:407–9. DOI: 10.1136/ard.2006.054205. PMID: 16926186. PMCID: PMC1856019.

44. Son KM, Song SH, Lim SK, Seo YI, Kim HA. 2012; Characteristics of patients with rheumatoid arthritis in clinical remission: the many aspects of DAS28 remission. Clin Exp Rheumatol. 30:947–50. PMID: 22935437.

45. Lee SW, Kim SY, Chang SH. 2019; Prevalence of feet and ankle arthritis and their impact on clinical indices in patients with rheumatoid arthritis: a cross-sectional study. BMC Musculoskelet Disord. 20:420. DOI: 10.1186/s12891-019-2773-z. PMID: 31506089. PMCID: PMC6737695.

46. Hensor EMA, Conaghan PG. 2020; Time to modify the DAS28 to make it fit for purpose(s) in rheumatoid arthritis? Expert Rev Clin Immunol. 16:1–4. DOI: 10.1080/1744666X.2019.1697679. PMID: 31790310.

47. Baker JF, Conaghan PG, Smolen JS, Aletaha D, Shults J, Emery P, et al. 2014; Development and validation of modified disease activity scores in rheumatoid arthritis: superior correlation with magnetic resonance imaging-detected synovitis and radiographic progression. Arthritis Rheumatol. 66:794–802. DOI: 10.1002/art.38304. PMID: 24757132.

48. Hensor EMA, McKeigue P, Ling SF, Colombo M, Barrett JH, Nam JL, et al. 2019; Validity of a two-component imaging-derived disease activity score for improved assessment of synovitis in early rheumatoid arthritis. Rheumatology (Oxford). 58:1400–9. DOI: 10.1093/rheumatology/kez049. PMID: 30824919. PMCID: PMC6649844.

49. Radner H, Smolen JS, Aletaha D. 2014; Remission in rheumatoid arthritis: benefit over low disease activity in patient-reported outcomes and costs. Arthritis Res Ther. 16:R56. DOI: 10.1186/ar4491. PMID: 24555808. PMCID: PMC3979137.

50. Chung SW, Choi JY, Lee SH, Song R, Yang HI, Hong SJ, et al. 2020; Predicting imaging remission in rheumatoid arthritis: a case-control ultrasound study. J Korean Med Sci. 35:e260. DOI: 10.3346/jkms.2020.35.e260. PMID: 32776721. PMCID: PMC7416004.

51. Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, et al. 2011; American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum. 63:573–86. DOI: 10.1002/art.30129. PMID: 21294106. PMCID: PMC3115717.

52. Studenic P, Smolen JS, Aletaha D. 2012; Near misses of ACR/EULAR criteria for remission: effects of patient global assessment in Boolean and index-based definitions. Ann Rheum Dis. 71:1702–5. DOI: 10.1136/annrheumdis-2012-201519. PMID: 22736085.

53. Studenic P, Felson D, de Wit M, Alasti F, Stamm TA, Smolen JS, et al. 2020; Testing different thresholds for patient global assessment in defining remission for rheumatoid arthritis: are the current ACR/EULAR Boolean criteria optimal? Ann Rheum Dis. 79:445–52. DOI: 10.1136/annrheumdis-2019-216529. PMID: 37080714.

54. Studenic P, Aletaha D, de Wit M, Stamm TA, Alasti F, Lacaille D, et al. 2023; American College of Rheumatology/EULAR remission criteria for rheumatoid arthritis: 2022 revision. Arthritis Rheumatol. 75:15–22. DOI: 10.1002/art.42347. PMID: 36274193. PMCID: PMC10092655.

55. Messelink MA, den Broeder AA, Marinelli FE, Michgels E, Verschueren P, Aletaha D, et al. 2023; What is the best target in a treat-to-target strategy in rheumatoid arthritis? Results from a systematic review and meta-regression analysis. RMD Open. 9:e003196. DOI: 10.1136/rmdopen-2023-003196. PMID: 37116986. PMCID: PMC10152050.

56. England BR, Barber CEH, Bergman M, Ranganath VK, Suter LG, Michaud K. 2021; Adaptation of American College of Rheumatology rheumatoid arthritis disease activity and functional status measures for telehealth visits. Arthritis Care Res (Hoboken). 73:1809–14. DOI: 10.1002/acr.24429. PMID: 32813284. PMCID: PMC7461171.

57. Jackson LE, Edgil TA, Hill B, Owensby JK, Smith CH, Singh JA, et al. 2022; Telemedicine in rheumatology care: a systematic review. Semin Arthritis Rheum. 56:152045. DOI: 10.1016/j.semarthrit.2022.152045. PMID: 35843158.

58. Ferucci ED, Day GM, Choromanski TL, Freeman SL. 2022; Outcomes and quality of care in rheumatoid arthritis with or without video telemedicine follow-up visits. Arthritis Care Res (Hoboken). 74:484–92. DOI: 10.1002/acr.24485. PMID: 33053261. PMCID: PMC10695327.

59. Boone NW, Sepriano A, van der Kuy PH, Janknegt R, Peeters R, Landewé RBM. 2019; Routine Assessment of Patient Index Data 3 (RAPID3) alone is insufficient to monitor disease activity in rheumatoid arthritis in clinical practice. RMD Open. 5:e001050. DOI: 10.1136/rmdopen-2019-001050. PMID: 31908842. PMCID: PMC6927511.

60. Castrejón I, Pincus T. 2012; Patient self-report outcomes to guide a treat-to-target strategy in clinical trials and usual clinical care of rheumatoid arthritis. Clin Exp Rheumatol. 30(4 Suppl 73):S50–5. PMID: 23079199.